Olaparib as well as Pembrolizumab Strategy to BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence along with Metastasis: An incident Record.
Olaparib as well as Pembrolizumab Strategy to BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence along with Metastasis: An incident Record.